China Clears Eli Lilly’s Weight-Loss Drug, Only for Diabetes Now
Eli Lilly & Co. Mounjaro brand tirzepatide medication.
Photographer: George Frey/BloombergThis article is for subscribers only.
China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight-loss drugs in the world’s second-largest market.
Tirzepatide won approval from Chinese regulators for treating adults with type 2 diabetes, the US company announced in a statement Tuesday. Its use for chronic weight management is still under review, it said.